Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients

A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06495281

Enrollment

2044

Registered

2024-07-10

Start date

2023-10-26

Completion date

2025-12-03

Last updated

2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician: 1. Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin) 2. Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor) 3. Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\]) * patients with HbA1c results and who signed the written consent form

Exclusion criteria

\- Patients contraindicated for the approved use of Zemidapa Tab. or have participated in another clinical study within 12 weeks

Design outcomes

Primary

Measure	Time frame
change from baseline of HbA1c at 12 weeks	baseline, 12 weeks

Secondary

Measure	Time frame
the rate of subjects who reached the target value of less than 7% HbA1c	12 weeks

Countries

South Korea

Outcome results